{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-116370","form_type":"8-K","ticker":"QNRX","cik":"0001671502","company_name":"Quoin Pharmaceuticals, Ltd.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.009808+00:00","generated_at":"2026-06-08T06:56:54.569205+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Quoin reports positive Phase 2 data for QRX003 in Netherton Syndrome; cash $14M","bullets":["Five of six evaluable subjects showed negligible/absent pruritus after QRX003 treatment in open-label study.","All six subjects improved in Investigator skin scoring; favorable patient global assessment across metrics.","No safety concerns in either ongoing study; protocol amendments planned: eliminate lower 2% dose, twice-daily dosing.","Cash, equivalents and marketable securities $14.0M as of Sept 30, 2023; runway expected through end of 2024.","Net loss $2.1M for Q3 2023 vs $2.3M for Q3 2022; nine-month net loss $7.2M flat year-over-year."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-116370","json":"https://secwatch.observer/filing/0001104659-23-116370.json","markdown":"https://secwatch.observer/filing/0001104659-23-116370.md","text":"https://secwatch.observer/filing/0001104659-23-116370.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671502/000110465923116370/0001104659-23-116370-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671502/000110465923116370/tm2330370d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:56:54.569205+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1dab391b46b9f5a3ec9af0089caa67694c46b698","claim":"Quoin Pharmaceuticals, Ltd. reported the quarter ended September 30, 2023 results: net income approximately $2.1 million.","evidence_excerpt":"Net loss for the quarter ended September 30, 2023 was approximately $2.1 million compared to approximately $2.3 million for the quarter ended September 30, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671502/000110465923116370/0001104659-23-116370-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Net income","value":"approximately $2.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}